CHEK1 and osteosarcoma: One relevant example has been the extensive use of the U2OS osteosarcoma cell line to study DNA damage-induced checkpoint regulation [58, 59], yet this cell line turns out to be one of the few that is hypersensitive to Chk1 inhibition [14, 21], and consequently, the different responses to Chk1 inhibitors has been missed.